Pharmaceutical

Samsung Biologics to Spin Off Biosimilars Unit Samsung Biologics Biotech Samsung Biologics plans to spin off its biosimilars subsidiary, Samsung Bioepis, by October 2025 to address conflict-of-interest concerns and enhance investor value, while continuing strong growth in its CDMO business.
Novo Nordisk Targets Wegovy Growth with New Strategy Novo Nordisk Wegovy Novo Nordisk offers a discounted Wegovy price for new patients and launches the “Choose the Real Thing” campaign as the FDA ends compounded semaglutide sales. The company also intensifies legal action against compounders amid rising competition.
GSK Gains Ground in COPD Market with Nucala GSK FDA GSK’s Nucala has received FDA approval as an add-on treatment for eosinophilic COPD, positioning it against Dupixent. Backed by strong trial results, GSK targets $669M in peak annual sales for the new indication.
Zentiva to Launch eGERD Drug Across Europe AstraZeneca Zentiva Zentiva signs €220M deal with Cinclus Pharma to commercialize linaprazan glurate for eGERD treatment across Europe. The partnership marks Zentiva’s shift into specialty medicines.
FDA Requests COVID-19 Vaccine Label Updates on Heart Risks Moderna FDA BioNTech Pfizer The FDA has requested Pfizer/BioNTech and Moderna update COVID-19 vaccine labels to reflect myocarditis and pericarditis risks in males aged 16-25. This update aligns with new FDA vaccine approval guidelines focusing on high-risk groups.
Pfizer's Talzenna Label Bid Faces Setback FDA Pfizer The FDA’s advisory committee unanimously rejected Pfizer’s proposal to expand Talzenna’s use for prostate cancer patients without HRR mutations, citing insufficient evidence from the TALAPRO-2 trial.
Lilly Challenges Medicare's Exclusion of Obesity Drugs Eli Lilly Zepbound Eli Lilly challenges CMS's 2026 Medicare Part D ruling that excludes coverage for obesity drugs like Zepbound and Wegovy, citing risks to patient care and provider autonomy amid rising concerns over healthcare access and costs.
Sanofi Acquires Vigil Neuroscience for $470M Sanofi Alzheimers Sanofi acquires Vigil Neuroscience for $470M upfront, aiming to advance Alzheimer’s research with TREM2-targeting drug VG-3927. The deal may reach $600M with milestones and strengthens Sanofi’s neurology pipeline.
Sanofi Acquires Oral Alzheimer’s Drug VG-3927 for $470M Sanofi Biotech Sanofi acquires Vigil Neuroscience for $470M to gain rights to VG-3927, a promising once-daily oral TREM2 agonist for Alzheimer’s. The deal boosts Sanofi's position in neurodegenerative disease treatment innovation.
BioNTech Invests $1.3B in UK R&D and AI Centers BioNTech Biotech BioNTech announces a $1.3 billion investment in the UK to establish R&D hubs in Cambridge and London, create 400+ jobs, and launch an AI center to accelerate drug discovery and personalized therapies.